Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.

The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations. However, the functional effect of this variant on disease pathogenesis remains unclear. This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls. Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2(GC) genotype with the disease-associated TYK2(GG) genotype. Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines. These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype. This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2. The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.

[1]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[2]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[3]  M. Ban,et al.  A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis , 2010, European Journal of Human Genetics.

[4]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[5]  Moses Rodriguez,et al.  Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair , 2009, Proceedings of the National Academy of Sciences.

[6]  A. Dejean,et al.  A Role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis , 2009, Science Translational Medicine.

[7]  D. Clayton,et al.  The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes , 2009, Nature Genetics.

[8]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[9]  P. D. De Jager,et al.  Multiple sclerosis susceptibility alleles in African Americans , 2009, Genes and Immunity.

[10]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[11]  Ludwig Kappos,et al.  Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci , 2009, Nature Genetics.

[12]  Pablo Moscato,et al.  Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 , 2009, Nature Genetics.

[13]  M. Calaza,et al.  Replication of recently identified systemic lupus erythematosus genetic associations: a case–control study , 2009, Arthritis research & therapy.

[14]  Margaret A. Pericak-Vance,et al.  The role of the CD58 locus in multiple sclerosis , 2009, Proceedings of the National Academy of Sciences.

[15]  J. O’Shea,et al.  Selectivity and therapeutic inhibition of kinases: to be or not to be? , 2009, Nature Immunology.

[16]  James Wason,et al.  Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor , 2009, European Journal of Human Genetics.

[17]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[18]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[19]  G. Szot,et al.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.

[20]  Torsten Schwede,et al.  The SWISS-MODEL Repository and associated resources , 2008, Nucleic Acids Res..

[21]  A. Wilks.  The JAK kinases: not just another kinase drug discovery target. , 2008, Seminars in cell & developmental biology.

[22]  Stephen L. Hauser,et al.  The genetics of multiple sclerosis: SNPs to pathways to pathogenesis , 2008, Nature Reviews Genetics.

[23]  Rakesh Nagarajan,et al.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. , 2008, Blood.

[24]  L. Maier,et al.  The developing mosaic of autoimmune disease risk , 2008, Nature Genetics.

[25]  Silke Schmidt,et al.  Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.

[26]  H. Harbo,et al.  Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis , 2007, Nature Genetics.

[27]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[28]  N. Watanabe,et al.  Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. , 2007, Blood.

[29]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.

[30]  G. Uzé,et al.  IL-28 and IL-29: newcomers to the interferon family. , 2007, Biochimie.

[31]  D. C. Graham,et al.  Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. , 2007, Rheumatology.

[32]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part I: The role of infection , 2007, Annals of neurology.

[33]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[34]  B. Peters,et al.  Distinguishing cancer-associated missense mutations from common polymorphisms. , 2007, Cancer research.

[35]  T. Morio,et al.  Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. , 2006, Immunity.

[36]  J. O’Shea,et al.  Human tyk2 kinase deficiency: another primary immunodeficiency syndrome. , 2006, Immunity.

[37]  A. Mantovani,et al.  Macrophage diversity and polarization: in vivo veritas , 2006 .

[38]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[39]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[40]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.

[41]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[42]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[43]  Massimo Trucco,et al.  Monocytes are progressively activated in the circulation of pregnant women , 2002, Journal of leukocyte biology.

[44]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[45]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[46]  V. Kuchroo,et al.  IL-4, IL-10, IL-13, and TGF-β from an Altered Peptide Ligand-Specific Th2 Cell Clone Down-Regulate Adoptive Transfer of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of Immunology.

[47]  D. Mason,et al.  Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein‐specific Th2 cell lines generated in the presence of glucocorticoids and IL‐4 , 2000, European journal of immunology.

[48]  Manuel C. Peitsch,et al.  Protein Modeling by E-mail , 1995, Bio/Technology.

[49]  M. Fellous,et al.  Activation of the protein tyrosine kinase tyk2 by interferon alpha/beta. , 1994, European journal of biochemistry.

[50]  W. Paul,et al.  Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease , 1994, Journal of Neuroimmunology.

[51]  R. Rudick,et al.  Diagnostic criteria for multiple sclerosis research involving multiply affected families. , 1991, Archives of neurology.

[52]  W. Schlick.  [The role of infection]. , 1988, Praxis und Klinik der Pneumologie.

[53]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[54]  A. Svejgaard,et al.  HL-A antigens and multiple sclerosis. , 1972, Lancet.

[55]  亜希子 小山田.  Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis , 2010 .

[56]  J. Rossjohn,et al.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.

[57]  B. Beutler,et al.  Type I interferons (alpha/beta) in immunity and autoimmunity. , 2005, Annual review of immunology.

[58]  B. Beutler,et al.  TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .

[59]  Smith Rf,et al.  Pattern-induced multi-sequence alignment (PIMA) algorithm employing secondary structure-dependent gap penalties for use in comparative protein modelling. , 1992 .

[60]  R. F. Smith,et al.  Pattern-induced multi-sequence alignment (PIMA) algorithm employing secondary structure-dependent gap penalties for use in comparative protein modelling. , 1992, Protein engineering.